Zimmer Biomet (ZBH) Stock Forecast & Price Target

$100.90 -2.18 (-2.11%)

Closing price 09/15/2025 03:59 PM Eastern

Extended Trading

$101.00 +0.10 (+0.10%)

As of 09/15/2025 07:24 PM Eastern

Compare

Zimmer Biomet - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold

Based on 18 Analyst Ratings

Sell
2

Hold
7

Buy
9

Based on 18 Wall Street analysts who have issued ratings for Zimmer Biomet in the last 12 months, the stock has a consensus rating of "Hold." Out of the 18 analysts, 2 have given a sell rating, 7 have given a hold rating, and 9 have given a buy rating for ZBH.

Consensus Price Target

$111.00
10.01% Upside

According to the 18 analysts' twelve-month price targets for Zimmer Biomet, the average price target is $111.00. The highest price target for ZBH is $135.00, while the lowest price target for ZBH is $95.00. The average price target represents a forecasted upside of 10.01% from the current price of $100.90.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ZBH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZBH Analyst Ratings Over Time

Type	Current Forecast 9/16/24 to 9/16/25	1 Month Ago 8/17/24 to 8/17/25	3 Months Ago 6/18/24 to 6/18/25	1 Year Ago 9/17/23 to 9/16/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	7 Hold rating(s)	9 Hold rating(s)	11 Hold rating(s)	12 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$111.00	$111.44	$111.53	$125.17
Forecasted Upside	10.01% Upside	8.44% Upside	23.27% Upside	16.56% Upside
Consensus Rating	Hold	Hold	Hold	Hold

ZBH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZBH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zimmer Biomet Stock vs. The Competition

Type	Zimmer Biomet	Medical Companies	S&P 500
Consensus Rating Score	2.39	2.78	2.53
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	9.41% Upside	17,949.17% Upside	10.99% Upside
News Sentiment Rating	Positive News See Recent ZBH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/8/2025	UBS Group 4 of 5 stars	Danielle Antalffy Not Rated	Boost Target	Sell	$91.00 ➝ $96.00	-1.71%
8/8/2025	Royal Bank Of Canada 3 of 5 stars	Shagun Singh Not Rated	Boost Target	Outperform	$112.00 ➝ $115.00	+16.63%
8/8/2025	Raymond James Financial 4 of 5 stars	Jayson Bedford 1 of 5 stars	Boost Target	Outperform	$104.00 ➝ $113.00	+15.02%
8/7/2025	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
7/8/2025	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	In-Line	$102.00 ➝ $96.00	+3.69%
5/12/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$115.00 ➝ $101.00	+2.26%
5/7/2025	JMP Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Turkaly Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Outperform	$140.00 ➝ $125.00	+32.72%
5/6/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$101.00	+7.08%
5/6/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$138.00 ➝ $115.00	+27.29%
5/6/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$120.00 ➝ $104.00	+14.50%
Get the Latest News and Ratings for ZBH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Zimmer Biomet and its competitors with MarketBeat's FREE daily newsletter.
5/6/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cecilia Furlong Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$115.00 ➝ $95.00	+4.11%
5/6/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$128.00 ➝ $105.00	+15.83%
5/6/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$113.00 ➝ $98.00	+8.66%
5/6/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeff Johnson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$130.00 ➝ $115.00	+27.29%
4/14/2025	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
2/10/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Underweight	$118.00 ➝ $112.00	+10.88%
2/7/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
10/15/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$145.00 ➝ $135.00	+29.93%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Peer Perform
9/6/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Hold	$143.00 ➝ $119.00	+13.61%
7/10/2024	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$134.00 ➝ $120.00	+12.25%
7/1/2024	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. O'brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$140.00 ➝ $115.00	+5.96%
5/21/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$150.00	+25.89%
10/20/2023	Roth Mkm Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Neutral	$120.00	+14.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:40 AM ET.

Should I Buy Zimmer Biomet Stock? ZBH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 15, 2025. Please send any questions or comments about these Zimmer Biomet pros and cons to contact@marketbeat.com.

Zimmer Biomet
Bull Case

Here are some ways that investors could benefit from investing in Zimmer Biomet Holdings, Inc.:

The company reported earnings per share of $2.07 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
Zimmer Biomet has set its fiscal year 2025 guidance for earnings per share between 8.100 and 8.300, suggesting confidence in future profitability.
The current stock price is around $104, reflecting a positive market sentiment and potential for appreciation as the company continues to grow.
Analysts have a favorable outlook, with nine rating the stock as a Buy and an average price target of $111, indicating potential upside for investors.
The company has a consistent dividend payout, with a recent quarterly dividend of $0.24 per share, providing a steady income stream for investors.

Zimmer Biomet
Bear Case

Investors should be bearish about investing in Zimmer Biomet Holdings, Inc. for these reasons:

Despite recent earnings growth, the company has a relatively low return on equity of 12.76%, which may indicate less efficient use of shareholder equity compared to peers.
Some analysts have issued a Sell rating, reflecting concerns about the stock's valuation and potential market challenges.
The dividend payout ratio is currently at 23.36%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
Recent insider selling, including a senior vice president selling shares, could signal a lack of confidence in the stock's short-term performance.
Market volatility and economic uncertainties could impact the company's revenue growth, which was reported at 7.0% year-over-year but may face challenges ahead.

ZBH Forecast - Frequently Asked Questions

: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Zimmer Biomet is $111.00, with a high forecast of $135.00 and a low forecast of $95.00.
: 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZBH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZBH, but not buy additional shares or sell existing shares.
: According to analysts, Zimmer Biomet's stock has a predicted upside of 10.01% based on their 12-month stock forecasts.
: Over the previous 90 days, Zimmer Biomet's stock had 1 upgrade by analysts.
: Zimmer Biomet has been rated by research analysts at Evercore ISI, Raymond James Financial, Roth Capital, Royal Bank Of Canada, and UBS Group in the past 90 days.
: Analysts like Zimmer Biomet less than other "medical" companies. The consensus rating for Zimmer Biomet is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZBH compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:ZBH) was last updated on 9/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Stock Forecast & Price Target